Ukraine proposes $100 bln US weapons deal for security guarantees - FT
SAN JOSE - Outset Medical, Inc. (NASDAQ:OM), a company focused on innovative dialysis technology, announced today the appointment of Kevin O’Boyle to its Board of Directors and as chair of its Audit Committee. O’Boyle, a seasoned healthcare industry executive with over two decades of leadership experience, will replace Dale E. Jones, who has stepped down from the Board. The announcement comes as the company’s stock shows strong momentum, with InvestingPro data indicating a remarkable 47% return over the past week and a 34% gain in the last six months.
Kevin O’Boyle’s career includes financial leadership roles in various healthcare companies. His tenure as CFO for several publicly traded firms and his board positions in six public medical device companies have equipped him with a vast understanding of capital equipment and recurring revenue models. His previous board service includes Nevro Corp., which was acquired by Globus Medical, Inc. in April 2025, and GenMark Diagnostics, which was taken over by Roche in May 2021. O’Boyle also has experience with companies like Sientra, Inc., Wright Medical Group, Zeltiq Aesthetics, and Durata Therapeutics, and he is currently serving on the board of Carlsmed. According to InvestingPro data, Outset Medical maintains a strong liquidity position with a current ratio of 8.37, indicating robust short-term financial health.
Leslie Trigg, Chair and CEO of Outset, praised O’Boyle’s appointment, citing his relevant expertise as a valuable asset for the company’s growth. Trigg also acknowledged Dale E. Jones’s significant contributions to the company during his tenure.
Outset Medical is known for the Tablo® Hemodialysis System, a technology designed to simplify and reduce the cost of dialysis treatment. FDA-cleared for use from the hospital to home, Tablo serves as an all-in-one solution that facilitates dialysis delivery by anyone, anywhere. The system’s integrated water purification and on-demand dialysate production, along with its data analytics platform, aim to revolutionize dialysis care.
The information regarding these changes in Outset Medical’s board composition and the company’s background is based on a press release statement.
In other recent news, Outset Medical reported a revenue increase of 5.6% year-over-year, reaching $29.8 million in the first quarter, which exceeded both Oppenheimer’s and the consensus estimates. However, the company faced a significant earnings per share (EPS) miss, reporting a loss of $3.24 compared to the anticipated loss of $0.30. Despite the EPS shortfall, recurring revenue grew by 20% year-over-year to $22.7 million, highlighting strong sales performance. Oppenheimer maintained its Perform rating for Outset Medical, noting the company’s stable market conditions and ongoing sales transformation. The company’s gross margin improved significantly to 37.6%, reflecting progress in operational efficiency. Outset Medical’s management confirmed their full-year 2025 guidance, projecting revenues between $115 million and $125 million, aligning with analysts’ estimates. The company emphasized its focus on profitability and reducing cash usage, with plans to use less than $50 million in cash for the year. Furthermore, Outset Medical benefits from tariff exemptions, which support its financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.